IE892640L - Defective hepadnaviruses and producer cell line for vaccines¹and treatment of liver diseases and disorders - Google Patents

Defective hepadnaviruses and producer cell line for vaccines¹and treatment of liver diseases and disorders

Info

Publication number
IE892640L
IE892640L IE892640A IE264089A IE892640L IE 892640 L IE892640 L IE 892640L IE 892640 A IE892640 A IE 892640A IE 264089 A IE264089 A IE 264089A IE 892640 L IE892640 L IE 892640L
Authority
IE
Ireland
Prior art keywords
defective
genomes
packaging
hepadnavirus
hepadnaviruses
Prior art date
Application number
IE892640A
Other languages
English (en)
Original Assignee
Tate & Lyle Plc
Biotest Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tate & Lyle Plc, Biotest Pharma Gmbh filed Critical Tate & Lyle Plc
Publication of IE892640L publication Critical patent/IE892640L/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IE892640A 1988-08-16 1989-08-16 Defective hepadnaviruses and producer cell line for vaccines¹and treatment of liver diseases and disorders IE892640L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23281188A 1988-08-16 1988-08-16

Publications (1)

Publication Number Publication Date
IE892640L true IE892640L (en) 1990-02-16

Family

ID=22874695

Family Applications (1)

Application Number Title Priority Date Filing Date
IE892640A IE892640L (en) 1988-08-16 1989-08-16 Defective hepadnaviruses and producer cell line for vaccines¹and treatment of liver diseases and disorders

Country Status (8)

Country Link
EP (1) EP0380656A1 (xx)
AU (1) AU4315689A (xx)
DK (1) DK93390A (xx)
FI (1) FI901876A0 (xx)
IE (1) IE892640L (xx)
IL (1) IL91335A0 (xx)
WO (1) WO1990002176A1 (xx)
ZA (1) ZA896246B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656136B2 (en) * 1990-04-20 1995-01-27 General Hospital Corporation, The Methods of preventing viral replication
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
DE19517532C2 (de) * 1995-05-12 1999-10-28 Max Planck Gesellschaft HBV-Vektoren und Zellen zu ihrer Bereitstellung
EP0969863A4 (en) * 1996-09-18 2001-11-07 Univ Texas DEFECTIVE VIRAL INTERFERENCE PARTICLES AND THEIR USE.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers

Also Published As

Publication number Publication date
WO1990002176A1 (en) 1990-03-08
DK93390D0 (da) 1990-04-11
FI901876A0 (fi) 1990-04-12
EP0380656A1 (en) 1990-08-08
ZA896246B (en) 1990-06-27
AU4315689A (en) 1990-03-23
IL91335A0 (en) 1990-03-19
DK93390A (da) 1990-06-15

Similar Documents

Publication Publication Date Title
Casey Control of ADAR1 editing of hepatitis delta virus RNAs
Elias et al. A DNA binding protein specific for an origin of replication of herpes simplex virus type 1.
Huang Human cytomegalovirus. IV. Specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid
AU662304B2 (en) DNA construct for providing RNA therapy
Mensa-Wilmot et al. Reconstitution of a nine-protein system that initiates bacteriophage λ DNA replication
Bhat et al. Adenovirus mutants with DNA sequence perturbations in the intragenic promoter of VAI RNA gene allow the enhanced transcription of VAII RNA gene in HeLa cells
JP2003527856A5 (xx)
Xu et al. Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro
WO2001016312A3 (en) Nucleic acid based modulators of gene expression
Darlix et al. Binding sites of viral protein P19 onto Rous sarcoma virus RNA and possible controls of viral functions
Bean Jr et al. Transcriptase activity and genome composition of defective influenza virus
IE892640L (en) Defective hepadnaviruses and producer cell line for vaccines¹and treatment of liver diseases and disorders
KR920703118A (ko) 유전자 발현에 영향을 주는 다수의 표적반응요소를 가진 벡터
Casey RNA editing in hepatitis delta virus genotype III requires a branched double-hairpin RNA structure
Giantini et al. Reovirus type 3 genome segment S4: nucleotide sequence of the gene encoding a major virion surface protein
Cherrington et al. Upstream sequences and cap proximity in the regulation of polyadenylation in ground squirrel hepatitis virus
Jenson et al. Sequences of the Epstein-Barr virus (EBV) large internal repeat form the center of a 16-kilobase-pair palindrome of EBV (P3HR-1) heterogeneous DNA
Netter et al. Nucleotide sequence stability of the genome of hepatitis delta virus
EP0528903B1 (en) Methods of preventing viral replication
WO1999053087A3 (de) 5'-modifizierte nukleotide und ihre anwendung in der molekularbiologie und medizin
Srivastava Inhibition of oncorna virus and cellular DNA polymerases by natural and synthetic polynucleotides
IL124636A (en) Conditionally replicating viral vectors and their use
Jayan et al. Effects of conserved RNA secondary structures on hepatitis delta virus genotype I RNA editing, replication, and virus production
Meisel et al. Inhibition of hepatitis B virus DNA polymerase by 3′‐fluorothymidine triphosphate and other modified nucleoside triphosphate analogs
Korn et al. Adenovirus DNA synthesis in vitro is inhibited by the virus-coded major core protein